06:52 AM EDT, 07/16/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) reported Q2 adjusted earnings Wednesday of $2.77 per diluted share, down from $2.82 a year earlier.

Analysts polled by FactSet expected $2.68.

Reported sales for the quarter ended June 30 were $23.74 billion, up from $22.45 billion a year earlier.

Analysts surveyed by FactSet expected $22.85 billion.

For 2025, the pharmaceuticals giant lifted its adjusted EPS guidance to between $10.80 and $10.90, up from its previous forecast of $10.50 to $10.70, on reported sales of $93.2 billion to $93.6 billion, up from its previous guidance of $91.0 billion to $91.8 billion.

Analysts polled by FactSet expect non-GAAP EPS of $10.64 on revenue of $91.43 billion.

Shares of the company were up more than 1% in recent Wednesday premarket activity.